{
    "clinical_study": {
        "@rank": "85802", 
        "arm_group": {
            "arm_group_label": "Enoxaparin sodium", 
            "arm_group_type": "Experimental", 
            "description": "Enoxaparin sodium (80mg) is administered subcutaneously as a single dose, in 2 periods."
        }, 
        "brief_summary": {
            "textblock": "This is a pilot, open-label study aimed at a preliminary evaluation of enoxaparin\n      bioavailability following two administrations of Clexane s.c. at a dose of 80mg, in two\n      different periods."
        }, 
        "brief_title": "A Single-Dose Study to Examine the Within Subject Variability of Clexane\u00ae in Healthy Adult Subjects Under Fasting Conditions", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Clexane is Administered to Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or female volunteer between 18 and 55 years of age.\n\n          -  Female subject of child bearing potential with a negative pregnancy test at the\n             Screening Visit and willing to use 2 effective methods of contraception  from Day 1\n             until 3 months afterwards.\n\n          -  Subject with no clinically significant abnormal serum biochemistry, haematology,\n             coagulation factors and urine examination values within 14 days of the first dose.\n\n        Exclusion Criteria:\n\n          -  Female subject with weight < 45 kg or male subject with weight < 57 kg.\n\n          -  Subject with clinically relevant abnormal physical findings which could interfere\n             with the objective of the study.\n\n          -  Subject with clinically relevant abnormal laboratory values indicative of physical\n             illness; Hemoglobin <13 g/dL; Absolute platelet count below 100 x 109/L.\n\n          -  Subject with hypersensitivity or idiosyncratic reaction to enoxaparin and/or low\n             molecular weight heparins, and/or pork products.\n\n          -  Subject with a relevant history or presence of significant cardiovascular, pulmonary,\n             hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,\n             neurologic, or psychiatric disease. In addition, history or presence of: alcoholism\n             or drug abuse within the past year; clotting disorders; gastric or duodenal ulcers;\n             hypertension; retinopathy; deep venous thrombosis; pulmonary embolism; GI bleeding.\n\n          -  Subject with any clinically significant illness within 4 weeks prior to dosing.\n\n          -  Subject with recent use of NSAID and/or aspirin (within 4 weeks of first dose) or the\n             use of any pharmacological agents known to significantly induce or inhibit\n             drug-metabolizing enzymes within 30 days of the first dose.  No subject may take any\n             antibiotic agent known to interfere with intestinal microflora within 30 days of the\n             first dose. Subjects with any medical condition requiring regular treatment with\n             prescription drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081950", 
            "org_study_id": "ENOXA/13/1"
        }, 
        "intervention": {
            "arm_group_label": "Enoxaparin sodium", 
            "description": "comparison of 2 different administration of drug", 
            "intervention_name": "Enoxaparin sodium", 
            "intervention_type": "Biological", 
            "other_name": "Clexane"
        }, 
        "intervention_browse": {
            "mesh_term": "Enoxaparin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Merthyr Tydfil", 
                    "country": "United Kingdom", 
                    "zip": "CF48 4DR"
                }, 
                "name": "Simbec Research Ltd"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-Dose Study to Examine the Within Subject Variability of Clexane\u00ae (80 mg) s.c. in Healthy Adult Subjects Under Fasting Conditions", 
        "overall_official": {
            "affiliation": "Italfarmaco S.p.A.", 
            "last_name": "Paolo Bettica, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Blood samples will be taken at pre-dose, and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36 hrs. Samples will be measured for anti-FXa, anti-FIIa, Thrombin Generation Assay, Tissue Factor Pathway Inhibitor and Thrombin Activatable Fibrinolysis Inhibitor, as surrogate markers for their circulating concentrations of the drug", 
            "measure": "Within subject variability of Enoxaparin sodium given subcutaneously in Healthy volunteers", 
            "safety_issue": "No", 
            "time_frame": "10 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081950"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "description of adverse event profile in healthy volunteers after a single dose of Enoxaparin sodium s.c.", 
            "measure": "number of participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "10 days"
        }, 
        "source": "Chemi S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chemi S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}